Methods and compositions for controlling transgene expression in Natural Killer Cells are disclosed. Also, disclosed are RDEs which can be used to optimize expression of transgenes in NK cells following activation pf the NK cell through a receptor, e.g., CARs or T-cell receptors. CARs and transgene payloads can also be engineered into NK cells so that the transgene payload is expressed and delivered at desired times from the NK cell. Such CAR NK cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anticancer therapies.

The present application provides enhanced APCs for treating HPV-associated cancers. The enhanced APCs are capable of activating T cells in an HLA agnostic manner and are derived from input APCs in which at least one nucleic acid encoding an HPV antigen has been delivered intracellularly. In some aspects, the enhanced APCs are administered in combination with an immune checkpoint inhibitor, such as an antagonist of PD-1/PD-L1 and/or an antagonist of CTLA-4.

The present application provides enhanced APCs for treating HPV-associated cancers. The enhanced APCs are capable of activating T cells in an HLA agnostic manner and are derived from input APCs in which at least one nucleic acid encoding an HPV antigen has been delivered intracellularly. In some aspects, the enhanced APCs are administered in combination with an immune checkpoint inhibitor, such as an antagonist of PD-1/PD-L1 and/or an antagonist of CTLA-4.

The present invention relates to a compound of formula (I) for its use in the production of interleukin-10 by immune cells. The invention also relates to induced immune cells capable of producing interleukin 10. The invention also relates to the use of the induced immune cells in the prevention and/or treatment of immune-mediated diseases.

The present invention relates to a compound of formula (I) for its use in the production of interleukin-10 by immune cells. The invention also relates to induced immune cells capable of producing interleukin 10. The invention also relates to the use of the induced immune cells in the prevention and/or treatment of immune-mediated diseases.

The present disclosure is related to compositions and systems for inducing immune tolerance for transplanted cells, organ, or tissues in a transplant recipient. Also provided herein are methods of making and methods of administering tolerizing vaccines/regimen or preparatory regimens.

The present disclosure is related to compositions and systems for inducing immune tolerance for transplanted cells, organ, or tissues in a transplant recipient. Also provided herein are methods of making and methods of administering tolerizing vaccines/regimen or preparatory regimens.

An in-vitro or ex-vivo method for transiently modifying immune cells in a closed processing system is disclosed. The steps include: (i) providing immune cells from a biological liquid and/or from a resected tumor from a patient; (ii) purifying the immune cells; (iii) transfecting the purified immune cells with an inhibitory nucleic acid of a immunosuppressive regulator of the immune cells or with a nucleic acid of an immune enhancing factor; (iv) rebuffering the transfected immune cells into a physiological solution; (v) transferring the transfected immune cells into a container; wherein the transitions between steps (i) to (v) are in a closed container system; and a therapy using the transfected immune cells.

An in-vitro or ex-vivo method for transiently modifying immune cells in a closed processing system is disclosed. The steps include: (i) providing immune cells from a biological liquid and/or from a resected tumor from a patient; (ii) purifying the immune cells; (iii) transfecting the purified immune cells with an inhibitory nucleic acid of a immunosuppressive regulator of the immune cells or with a nucleic acid of an immune enhancing factor; (iv) rebuffering the transfected immune cells into a physiological solution; (v) transferring the transfected immune cells into a container; wherein the transitions between steps (i) to (v) are in a closed container system; and a therapy using the transfected immune cells.

The present disclosure provides for efficient ex vivo processes for generating B cell lineages from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and/or more closely resemble the corresponding lineage isolated from peripheral blood or lymphoid organs. The present invention in some aspects provides isolated cells and cell compositions produced by the methods disclosed herein, as well as methods for cell therapy.